Related Experiment Videos
Modification of DNA by mitomycin C in cancer patients detected by 32P-postlabeling analysis
1Biochemistry Division, National Cancer Center Research Institute, Tokyo, Japan.
Abstract:
DNA adducts of mitomycin C (MMC) were detected by 32P-postlabeling analysis in both surgical specimens and an autopsy sample of the liver of patients with hepatocellular carcinoma who had received chemotherapy with MMC. Four kinds of adducts were detected in all 6 patients treated with MMC. These adducts had identical chromatographic mobilities to those of adducts in the liver of rats treated with MMC, but 1 additional adduct was detected in rat liver. In patients treated with MMC, about 3 adducts/10(8) nucleotides were found 4 days after MMC treatment, and 1 adduct/10(8) nucleotides 14 days after treatment and the latter level was maintained for up to 56 days. MMC-DNA adducts were also detected in peripheral blood leukocytes from a patient 1 and 7 days after MMC treatment, at levels of 1 and 0.6 adduct/10(8) nucleotides, respectively. These results suggest the tumor-initiating activity of MMC in humans.
Insights
Mitomycin C (MMC) chemotherapy forms DNA adducts in liver cancer patients. These DNA adducts persist for weeks, suggesting Mitomycin C may initiate tumors in humans.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer.
- Mitomycin C (MMC) is a chemotherapeutic agent used in cancer treatment.
- Understanding the genotoxic effects of MMC is crucial for assessing its long-term risks.
Purpose of the Study:
- To detect and quantify DNA adducts of Mitomycin C (MMC) in patients with hepatocellular carcinoma (HCC).
- To investigate the persistence and levels of MMC-DNA adducts in human tissues and blood.
- To evaluate the potential tumor-initiating activity of MMC in humans.
Main Methods:
- 32P-postlabeling analysis was employed to detect DNA adducts.
- Analysis was performed on surgical specimens and autopsy liver samples from HCC patients treated with MMC.
- DNA adducts were also analyzed in peripheral blood leukocytes.
Main Results:
- Four types of MMC-DNA adducts were identified in all 6 HCC patients treated with MMC.
- Adduct levels were approximately 3 adducts/10^8 nucleotides at 4 days post-treatment, decreasing to 1 adduct/10^8 nucleotides by 14 days.
- Detectable adduct levels persisted for up to 56 days post-treatment.
- MMC-DNA adducts were also found in leukocytes 1 and 7 days after treatment.
Conclusions:
- The presence and persistence of MMC-DNA adducts in HCC patients indicate genotoxic exposure.
- These findings suggest a potential role for Mitomycin C in tumor initiation in humans.
- Further research is warranted to fully elucidate the carcinogenic potential of MMC.